LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Interview with… Juan Medina, Co-Founder & CEO at Kaffe Bueno

04/05/2021
INTERVIEW

About Juan Medina

Juan holds a Bachelor’s Degree in International Business and, before co-founding Kaffe Bueno in 2016, he worked as Business Development Consultant in London. Since then, Juan has led Kaffe Bueno in pushing the boundaries of what coffee is and should be by raising more 1.6M euros in private and public funding, establishing several commercial partnerships and started developing a biorefinery for full coffee’s utilization for manufacturing and launching various coffee derived ingredients, with many more on the pipeline with their respective IP.

Interview with... Juan Medina, Co-Founder & CEO at Kaffe Bueno

1) What inspired the foundation of Kaffe Bueno?
Since an early age, I was always frustrated that in Colombia – my home country – people considered that “normal” or the “usual way of doing business” was you needed to cheat, lie or steal for a successful profitable business.

Inspired by my father – a person with strong ethics, who I admired the most and who has always been entrepreneur since I can remember, I knew I wanted to pursue my own goals and make an impact. I always thought ‘recycled’ was the best way to go, combining all the key aspects economic, social and environmental activities I wanted to address.

Then in London, I was lucky enough to meet two partners with similar ambitions. We were introduced by our Scandinavian friends to the insane levels of coffee consumption in Scandinavia. This, combined with economic crisis in the coffee industry, where farmers were paid less than cost to grow coffee, whilst 99% of was going to waste, and we were inspired to address this huge resource inefficiency by valorising what was being considered as “waste”.

Remembering how my grandmother used to tell me to put grounds in my wounds for faster wound healing, or seeing her dye her hair with a coffee brew, helped us narrow down our focus on health-human centred applications and ignited the start of KB.

2) What coffee-derived products have you established so far?
Currently we have two products in the market. The first is an active lipid coffee derived extract which is being commercialized together with Givaudan, targeted towards the personal care industry due its outstanding properties. The second is an enriched, nutrient dense Coffee derived fiber, targeted towards the food and personal care industries.

3) What is the application of highest potential from your work so far?
Even though the adoption of our existing products is increasing day by day, we plan to launch several ingredients in the coming years, intended to replace harmful ingredients for human health and the environment within personal care, and also another targeting a significant chronic disease. I can’t say much more right now, but stay tuned and you will see!

4) What does Europe need to do to support SMEs like Kaffe Bueno to grow?
SMEs like KB (and in general in the bioeconomy sector) developing new processes and products, we need to establish new infrastructure, meaning CAPEX. More specific solutions for these needs are much needed, where not just Medium or Large companies are eligible. Furthermore, there is a need for efficient registration of ingredients in general, particularly within food and supplements. Animal testing is a BIG barrier for small companies due to its prohibitive costs and inefficiencies. Finding more efficient animal-free testing using organ-on-a-chip or in-vitro system that lower barriers of entry for small companies will accelerate all the exciting innovations across the EU and prevent them from going to the US or other geographies, where there are fewer barriers to entry for this type of innovation.

Download the full INTERVIEW below.

Interview with Kaffe Bueno


Download
2021_05_G_O_Interview-with…-Kaffe-BuenoDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
10/04/2025

EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.